Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous SVF for Type 2 Diabetes Mellitus
NCT07487467Recruiting
- Sponsor
- Kaiser Permanente
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous adipose-derived stromal vascular fraction in type 2 diabetes mellitus (T2DM), sponsored by Kaiser Permanente. Primary endpoint: Fasting Plasma Glucose at 6 months. Started Jan 2025; status: recruiting.
02
Drugs
autologous adipose-derived stromal vascular fraction
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07487467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487467.